Vir Biotechnology
About: Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Employees: 587
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
15% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 67
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
2.3% less ownership
Funds ownership: 67.21% [Q2] → 64.92% (-2.3%) [Q3]
9% less funds holding
Funds holding: 215 [Q2] → 195 (-20) [Q3]
18% less capital invested
Capital invested by funds: $814M [Q2] → $664M (-$149M) [Q3]
44% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 39
86% less call options, than puts
Call options by funds: $1.28M | Put options by funds: $8.95M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$14
38%
upside
Avg. target
$35
245%
upside
High target
$110
988%
upside
6 analyst ratings
5 positive
83%
1 neutral
17%
0 negative
0%
Leerink Partners Roanna Ruiz 33% 1-year accuracy 3 / 9 met price target | 98%upside $20 | Outperform Maintained | 13 Jan 2025 |
HC Wainwright & Co. Patrick Trucchio 27% 1-year accuracy 42 / 156 met price target | 988%upside $110 | Buy Reiterated | 10 Jan 2025 |
Morgan Stanley Michelle Gilson 0% 1-year accuracy 0 / 1 met price target | 98%upside $20 | Overweight Upgraded | 9 Jan 2025 |
JP Morgan Eric Joseph 41% 1-year accuracy 12 / 29 met price target | 38%upside $14 | Neutral Maintained | 9 Jan 2025 |
Needham Joseph Stringer 24% 1-year accuracy 31 / 128 met price target | 88%upside $19 | Buy Reiterated | 20 Nov 2024 |
Financial journalist opinion
Based on 7 articles about VIR published over the past 30 days
Positive
Seeking Alpha
1 week ago
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.
Positive
Benzinga
1 week ago
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
On Wednesday, Vir Biotechnology, Inc. VIR presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid tumors, and VIR-5500, which targets PSMA in metastatic castration-resistant prostate cancer (mCRPC).
Positive
Zacks Investment Research
1 week ago
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates
Vir Biotechnology posts encouraging initial data from phase I studies evaluating VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors.
Positive
Seeking Alpha
1 week ago
Vir Biotechnology: A Rocket Off Phase 1 Data
Vir Biotechnology's recent share price rally is driven by their promising cancer program, despite their primary focus on hepatitis management. The company's market cap has surged past $1 billion, raising questions about the sustainability and justification of this valuation. The early data for their T cell engagers suggest favorable safety, with hints of efficacy and a boatload more patients in phase 1 waiting for more evaluation.
Positive
Benzinga
1 week ago
Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why
On Wednesday, Vir Biotechnology, Inc. VIR stock traded higher after the company presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid tumors, and VIR-5500, which targets PSMA in metastatic castration-resistant prostate cancer (mCRPC).
Positive
Investors Business Daily
1 week ago
Vir Biotechnology Catapults 62% On Promising Results In Cancer Treatment
Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double digits. The post Vir Biotechnology Catapults 62% On Promising Results In Cancer Treatment appeared first on Investor's Business Daily.
Neutral
Business Wire
1 week ago
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today is presenting initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, targeting a variety of HER2-expressing solid tumors; and VIR-5500, targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC). Data show encouraging preliminary safety and efficacy profiles with no dose-limiting cytokine release syndrome (CRS), maximum tolerated dose (MTD) not yet reached as dose escalation co.
Neutral
Business Wire
1 month ago
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, at 4:30 p.m. PT in San Francisco, California. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website at www.vir.bio and will be archived there for 30 days. About.
Positive
Seeking Alpha
1 month ago
Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January
VIR's is expected to report data in January from two phase 1 trials of VIR-5500 and VIR-5818, two T-cell engagers, in various cancer types. JANX recently produced promising data with JANX007, which is similar to VIR-5500, in prostate cancer. As for elebsiran and tobevibart, two treatments for hepatitis B and hepatitis delta, a phase 3 program in hepatitis delta will get underway in H1'25.
Neutral
Business Wire
1 month ago
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation and European Medicines Agency (EMA) Priority Medicines (PRIME) designation for the treatment of chronic hepatitis delta (CHD). The designations are supported by compelling positive safety and efficacy data from the Phase 2 SOLSTICE trial, from which the Company recently presented new data at AAS.
Charts implemented using Lightweight Charts™